uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Genetic predictors of controlled ovarian hyperstimulation: where do we stand today?
Division of Obstetrics and Gynaecology, Dept of Clinical Science, Karolinska University Hospital Huddinge, Sweden. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Division of Obstetrics and Gynaecology, Dept of Clinical Science, Karolinska University Hospital Huddinge, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Competence Centre on Reproductive Medicine and Biology, Tartu, Estonia.
2011 (English)In: Human Reproduction Update, ISSN 1355-4786, E-ISSN 1460-2369, Vol. 17, no 6, 813-828 p.Article, review/survey (Refereed) Published
Abstract [en]


Nowadays, the use of IVF has improved the prospects of infertility treatment. The expected outcome of IVF depends greatly on the effectiveness of controlled ovarian hyperstimulation (COH), where exogenous gonadotrophins are used to induce folliculogenesis. The response to stimulation varies substantially among women and is difficult to predict. Several predictive markers of COH outcome have been proposed (e.g. maternal age and ovarian reserve), but the search for optimal predictors is ongoing. Pharmacogenetic studies demonstrate the effects of individual genetic variability on COH outcome and the potential for customizing therapy based on the patient's genome.


MEDLINE, EMBASE, DARE, CINAHL and the Cochrane Library, and references from relevant articles were investigated up to February 2011 regarding any common genetic variation and COH/IVF outcome.


Several polymorphisms in genes involved in FSH signalling, estrogen biosynthesis, folliculogenesis, folate metabolism and other aspects influence the response to exogenous gonadotrophin administration, resulting in differences in COH and IVF outcomes. Nevertheless, the most studied polymorphism FSHR Asn680Ser is practically the only genetic marker, together with ESR1 PvuII T/C, that could be applied in clinical tests.


Although data are accumulating with evidence suggesting that the ovarian response to COH is mediated by various polymorphisms, the optimal biomarkers and the efficacy of the tests still remain to be evaluated.

Place, publisher, year, edition, pages
2011. Vol. 17, no 6, 813-828 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-159600DOI: 10.1093/humupd/dmr034ISI: 000295984700008PubMedID: 21862569OAI: oai:DiVA.org:uu-159600DiVA: diva2:445698
Available from: 2011-10-04 Created: 2011-10-04 Last updated: 2013-02-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Altmäe, SigneStavreus-Evers, Anneli
By organisation
Department of Women's and Children's Health
In the same journal
Human Reproduction Update
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 161 hits
ReferencesLink to record
Permanent link

Direct link